🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting more than 82 million instances each year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the face of rising global incidence, the spread of superbugs and the extremely scarce available drugs currently available.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The trial enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in many regions with limited resources.

Clinicians on the front lines have expressed positive views. Access to a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is deemed vital to lessen the impact of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.